Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis

Prostate‐specific antigen (PSA) screening and concomitant treatment can be implemented in several ways. The authors investigated how the net benefit of PSA screening varies between common practice versus “good practice.”

[1]  Douglas K Owens,et al.  Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[2]  Steven L. Chang,et al.  Systematic Review of the Volume-Outcome Relationship for Radical Prostatectomy. , 2017, European urology focus.

[3]  M. Cooperberg,et al.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.

[4]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[5]  Hans Lilja,et al.  It ain't what you do, it's the way you do it: five golden rules for transforming prostate-specific antigen screening. , 2014, European urology.

[6]  S. Eggener,et al.  National trends in prostate cancer screening among older American men with limited 9‐year life expectancies: Evidence of an increased need for shared decision making , 2014, Cancer.

[7]  Andrew J Vickers,et al.  Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen , 2014, BMC Medicine.

[8]  Kirsten L. Greene,et al.  Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.

[9]  D. Howard.  Declines in prostate cancer incidence after changes in screening recommendations. , 2012, Archives of internal medicine.

[10]  H. D. de Koning,et al.  Quality-of-life effects of prostate-specific antigen screening. , 2012, The New England journal of medicine.

[11]  Andrew J Vickers,et al.  Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[13]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[14]  S. Eggener,et al.  Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  B. Guillonneau,et al.  Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. , 2011, European urology.

[16]  Andrew J. Vickers,et al.  The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group , 2010, Clinical Cancer Research.

[17]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  John T. Wei,et al.  Prostate cancer early detection , 2010 .

[19]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[20]  A. Vickers,et al.  Low annual caseloads of United States surgeons conducting radical prostatectomy. , 2009, The Journal of urology.

[21]  J. Eastham.  Do high-volume hospitals and surgeons provide better care in urologic oncology? , 2009, Urologic oncology.

[22]  A. Vickers,et al.  Estimating the benefits of PSA screening , 2022 .

[23]  E. Feuer,et al.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.

[24]  Wadih Arap,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[25]  M. Kattan,et al.  The surgical learning curve for prostate cancer control after radical prostatectomy. , 2007, Journal of the National Cancer Institute.

[26]  P. Walsh,et al.  Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.

[27]  J. Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[28]  P. Walsh.  Variations in morbidity after radical prostatectomy. , 2002, The Journal of urology.

[29]  A Milstein,et al.  Improving the safety of health care: the leapfrog initiative. , 2000, Effective clinical practice : ECP.

[30]  A. Enthoven,et al.  Should operations be regionalized? The empirical relation between surgical volume and mortality. , 1980, The New England journal of medicine.

[31]  David C. Miller,et al.  Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. , 2015, European urology.

[32]  Liying Zhang,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.